Drug recall · September 4, 2019
RELPAX (eletriptan HBr) tablets recall
Why: Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY 10017.
- Lots / codes
Lot #: a) AR5407, Exp 2022 FEB; b) CD4565, Exp 2022 FEB
- Quantity
- a) 20,117 cartons; b) 2,502 cartons
- Company
- Pfizer Inc., New York, NY
- Distribution
- Nationwide in the USA and Puerto Rico.
- Initiated
- August 14, 2019 · Voluntary: Firm initiated
- Classified
- August 28, 2019
- Reported
- September 4, 2019
- Ended
- June 20, 2023
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Eletriptan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.